Instrument Inactif

Communiqués Epizyme, Inc.

Actions

EPZM

US29428V1044

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology	15/08/22	AQ
EPIZYME, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	12/08/22	AQ
Epizyme : Reports Second Quarter 2022 Financial Results and Provides Business Update - Form 8-K	09/08/22	PU
EPIZYME, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/08/22	AQ
Epizyme: Q2 Earnings Snapshot	09/08/22	AQ
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update	09/08/22	BU
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022	08/08/22	AQ
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM	13/07/22	BU
EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM	28/06/22	BU
Epizyme : Ipsen to acquire Epizyme, expanding its portfolio in oncology - Form 8-K	27/06/22	PU
EPIZYME, INC. : Entry into a Material Definitive Agreement, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	27/06/22	AQ
Ipsen to acquire Epizyme, expanding its portfolio in oncology	27/06/22	BU
Ipsen acquiert Epizyme et étend son portefeuille en Oncologie	27/06/22	BU
Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology	27/06/22	BU
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting	02/06/22	BU
EPIZYME, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	24/05/22	AQ
EPIZYME, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	19/05/22	AQ
Epizyme To Participate in H.C. Wainwright Global Investment Conference	17/05/22	BU
EPIZYME, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	10/05/22	AQ
Epizyme: Q1 Earnings Snapshot	10/05/22	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Epizyme, Inc.

Actions

EPZM

US29428V1044

Communiqués

Filtres